Evidence map›Paper›PMID 39576151›Full record

ArticleAIDS (London, England)2025

SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa.

Emmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, Guillaume Thaurignac, Nnakelu Eriobu, Margaret Borok, Richard Kaplan, Anchalee Avihingsanon, Iskandar Azwa, Beatriz Grinsztejng and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Emmanuelle PapotTherapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
Tamara Tovar-SanchezTransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France.
Joana WoodsEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Guillaume ThaurignacTransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France.
Nnakelu EriobuInstitute of Human Virology Nigeria, Abuja, Nigeria.
Margaret BorokUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Richard KaplanDesmond Tutu Health Foundation, Cape Town, South Africa.
Anchalee AvihingsanonThe HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Iskandar AzwaInfectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Beatriz GrinsztejngInstituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Brazil.
Nagalingeswaran KumarasamyChennai Antiviral Research and Treatment Clinical Research Site, Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India.
Simiso SokhelaEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Mireille Mpoudi-EtameMilitary Hospital Region N°1, Yaoundé, Cameroon.
Maria ArriagaTherapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
Simone JacobyTherapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
Gail V MatthewsTherapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
Marcelo H LossoCoordinación en Investigación Clínica Académica en Latinoamérica Fundación IBIS Buenos Aires, Argentina.
Saye KhooDepartment of Molecular and Clinical Pharmacology University of Liverpool, Liverpool, UK.
Alexandra CalmyHIV/AIDS Unit Director, Geneva University Hospitals, Geneva, Switzerland.
Charles KouanfackCentral Hospital of Yaoundé, Yaoundé, Cameroon.
Ahidjo AyoubaTransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France.
Kathy PetoumenosBiostatistics and Databases Program, The Kirby Institute, University of New South Wales Sydney, NSW.
W D Francois VenterEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Eric DelaporteTransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France.
Mark N PolizzottoTherapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
COHIVE study group

Funding

NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

objectiveData on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey, between January and March 2021, while characterizing participants' features.

designCross-sectional serosurvey.

methodsDemographic characteristics, medical history and a serum sample were collected from consenting PWH. Samples were analyzed centrally for immunoglobulin G antibodies to recombinant nucleocapsid and spike proteins derived from SARS-CoV-2 using a Luminex based assay.

resultsThe 549 participants recruited in 9 sites across Africa had a median age of 40 years (interquartile range, IQR [34-45]); 63.0% (346) were female. All were on ART; 81.8% (449) had an HIV-1 viral load <50 copies/ml, with CD4 + cell count median at 478/mm 3 (IQR [320-677]). None had received vaccination against SARS-CoV-2. Forty participants (7.3%) had a prior SARS-CoV-2 PCR testing, of whom 10 were positive (1.8%). Crude SARS-CoV-2 seroprevalence was 36.2% (95% confidence interval (CI) [32.2-40.4]). In the explorative multivariable analysis, comparison of the characteristics of PWH with a positive SARS-CoV-2 serology with those with a negative or indeterminate serology: PWH with a body mass index (BMI) ≥30 kg/m 2 were more likely to have a positive serology than those with a BMI <25 (adjusted odds ratio (aOR) = 2.39 [1.48-3.86], P  < 0.001); and PWH living in Cameroon were less likely to have a positive serology.

conclusionThis study demonstrates a substantial seroprevalence level of SARS-CoV-2 in PWH in the first quarter of 2021, with a marked disparity with the number of COVID-19 PCR tests reported positive.

Indexed as

COVID-19HIV InfectionsSARS-CoV-2AdultAfricaAntibodies, ViralCross-Sectional StudiesFemaleHIV-1HumansImmunoglobulin GMaleMiddle AgedRandomized Controlled Trials as TopicSeroepidemiologic StudiesAntibodies, ViralImmunoglobulin G

Identifiers

PMID39576151
PMCPMC11864883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.